27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Catalyst
The biopharmaceutical company specializing in antibody-based therapeutics announced that it has inked an exclusive global licensing agreement with Seattle Genetics, Inc. (NASDAQ:SGEN) for its Sacituzumab Govitecan, code named IMMU-32. The treatment candidate has the potential for being the first ever approved therapy specifically for advanced metastatic triple-negative breast cancer. Immunomedics stands to gain potential payments of up to about $2 billion, plus royalties.
Separately, the company announced postponement of its 2016 Annual Meeting of Stockholders previously scheduled for February 16. The meeting has been postponed to March 3 at 10:00 a.m. ET.
Payment Breakup
Buy at this blue line for a shot at trading profitably
There are so many indicators out there on when to buy and sell. Nic uses none. He looks at a chart and buys when a stock “pushes” off this blue line. What blue line? Find out on the next page. It’ll change how you make money from stocks. Click here for the details.
- Upfront cash payment: $250 million.
- Among other milestone payments, an additional $50 million or negotiated economic splits relating to rights outside the United States, Canada and the EU.
- Milestone payments of up to $1.7 billion.
- Seattle Genetics to make up to $57 million equity investment for up to 9.9 percent stake in Immunomedics through purchase of 3 million common stock representing a 2.8 percent stake and a three-year warrant.
Other Terms
The agreement provides for Seattle Genetics developing manufacturing and commercializing IMMU-132 in multiple locations, while Immunomedics would retain rights to co-promote in the United States.
Shkreli Recommends Shorting
In a Facebook Inc (NASDAQ:FB) post, Martin Shkreli said he would short Immunomedics on the bounce. "I can't believe they got $250 million for this irinotecan prodrug. The world has moved on from old chemo mechanisms to targeted/IO. That'll be the last $250 they get," he said in the post.
At Time Of Writing
- Immunomedics was skyrocketing 20.42 percent to $5.17.
- Seattle Genetics was slipping 3.26 percent to $60.76.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.